January 1, 2014Open Access

Identification of longitudinally dynamic biomarkers in Alzheimer’s disease cerebrospinal fluid by targeted proteomics

KWKristin R. WildsmithEisai (United States)SSStephen SchauerGenentech ASAshley M. SmithUniversity of Wyoming

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Using a targeted proteomics approach, we confirmed previous findings for a subset of markers, defined longitudinal performance of our panel of markers, and established a flexible proteomics method for robust multiplexed analyses.

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Cite This Study

Wildsmith et al. (Wed,) studied this question.

synapsesocial.com/papers/69d8097d3eff0c9dfaae3178 https://doi.org/https://doi.org/10.1186/1750-1326-9-22

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Albumin depletion of human plasma also removes low abundance proteins including the cytokines2005 · 223 citations
2Quantitative analysis of complex protein mixtures using isotope-coded affinity tags1999 · 4,657 citations
3Cerebrospinal fluid diagnostic markers correlate with lower plasma copper and ceruloplasmin in patients with Alzheimer’s disease2006 · 79 citations
4Identification and Validation of Novel Cerebrospinal Fluid Biomarkers for Staging Early Alzheimer's Disease2011 · 175 citations
5Proteomic Changes in Cerebrospinal Fluid of Presymptomatic and Affected Persons Carrying Familial Alzheimer Disease Mutations2012 · 125 citations

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo